March 2025 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between Feb. 21, 2025, through March 21, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24190 | USOR 24190 LUN 571 Phase 3 Maintenance BMS-986012 or Atezolizumab Q28D
USOR 24190 LUN 571 Phase 3 Induction BMS-986012 or Atezolizumab + Carboplatin + Etoposide D1-3 Q21D |
| 24149 | USOR 24149 LUN 572 Phase 3 Arm A Nivolumab/Relatlimab + Pemetrexed + Carboplatin Q21D
USOR 24149 LUN 572 Phase 3 Arm A Nivolumab/Relatlimab + Pemetrexed + Cisplatin Q21D USOR 24149 LUN 572 Phase 3 Arm B Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 24149 LUN 572 Phase 3 Arm B Pembrolizumab + Pemetrexed + Cisplatin Q21D |
| 24100 | USOR 24100 GYN 133 Phase 2 Sapanisertib + Serabelisib + Paclitaxel Q28D |
| 23271 | USOR 23271 MEL 80 Phase 3 Randomized Nivolumab IV Week 21+ Q28D
USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Dacarbazine D1-5 Q21D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Nab-Paclitaxel D1,8,15 Q28D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Nivolumab + Relatlimab (Opdualag) Q28D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Nivolumab Monotherapy D1 or D1,15 Q28D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Paclitaxel Q21D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Pembrolizumab Q21D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Pembrolizumab Q42D USOR 23271 MEL 80 Phase 3 Randomized Physician’s Choice Temozolomide D1-5 Q28D USOR 23271 MEL 80 Phase 3 Randomized Vusolimogene Oderparepvec (VO) ITU + Nivolumab IV Q14D USOR 23271 MEL 80 Phase 3 Vusolimogene Oderparepvec (VO) Additional Courses Q14D |
| 24312 | USOR 24312 LUN 567 Phase 2 Arm A BMS-986489 Q28D
USOR 24312 LUN 567 Phase 2 Arm B Durvalumab Q28D |
| 24175 | USOR 24175 RM 1016 Phase 1 Part A FX-909 Q28D |
| 24112 | USOR 24112 GYN 136 Phase 2 TORL-1-23 Q21D |
| 24146 | USOR 24146 GI 384 Phase 3 Arm A RMC-6236 Q28D
USOR 24146 GI 384 Phase 3 Arm B Liposomal Irinotecan (Nal-IRI) + Fluorouracil + Leucovorin Q28D USOR 24146 GI 384 Phase 3 Arm B Nab-paclitaxel + Gemcitabine (GnP) Q28D USOR 24146 GI 384 Phase 3 Arm B Oxaliplatin + Leucovorin + 5-fluorouracil (FOLFOX) Q28D USOR 24146 GI 384 Phase 3 Arm B Oxaliplatin + Leucovorin + Irinotecan + 5-fluorouracil (mFOLFIRINOX) Q28D |
| 24151 | USOR 24151 BRE 444 Phase 3 Elacestrant Q28D
USOR 24151 BRE 444 Phase 3 SoC Endocrine Therapy Q28D |
| 24171 | USOR 24171 LUN 586 Phase 3 Rilvegostomig or Pembrolizumab + Pemetrexed + Carboplatin fb Rilvegostomig or Pembrolizumab + Pemetrexed Q21D
USOR 24171 LUN 586 Phase 3 Rilvegostomig or Pembrolizumab + Pemetrexed + Cisplatin fb Rilvegostomig or Pembrolizumab + Pemetrexed Q21D |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 23294 | Version 020-04: 12 Dec 2024. | NA | NA | Updated drug instruction to include weight-based dosing and stability |
| 22320 | Version 3.0: 09 July 2024 | NA | Updated observation time | NA |
| 24073 | Amendment 4/US-2: 18 Dec 2024. | NA | NA | Combined Cycle 1 and 2+ regimens. Separated Part 1 and Part 2 regimens. |
| 24018 | Version 2.0: 24 Oct 2024. | NA | NA | NA |
| 23247 | Version 4.0: 23 Sep 2024. | NA | NA | Added SoC substitutions |
| 22333 | Amendment 4 Version 5: 29 Nov 2024 | NA | NA | NA |
| 22297 | Version 3.0: 22 July 2024. | NA | NA | Corrected regimen schedule |
| 24093 | NA | NA | NA | Updated IP name. |
| 24010 | NA | NA | NA | Updated Venetoclax dispensation schedule |
| 23099 | Amendment 02: 19 Dec 2024. | NA | Updated premedication wording | NA |
| 23223 | Added: Local Amendment 4.0: 18 Dec 2024. | NA | NA | NA |
| 20266 | Version 6.1: 20 Dec 2024. | NA | NA | NA |
| 21181 | Amendment 4: 14 Nov 2024. | NA | NA | NA |
| 22333 | Amendement 5 (Version 6): 21 Jan 2025. | NA | NA | NA |
| 23228 | Version 4.0: 12 November 2024 | NA | Updated prophylaxis. Added BSA wording. | NA |
| 23156 | Version 4.0: 01OCT2024. | Updated cycle length | Update administration duration | Added additional administration schedule. |
| 21498 | Version 5.0: 13 Sep 2024. | NA | NA | NA |